<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04158674</url>
  </required_header>
  <id_info>
    <org_study_id>ELLOUZE_ORION_2018</org_study_id>
    <nct_id>NCT04158674</nct_id>
  </id_info>
  <brief_title>Interest of Levosimendan in Reducing Weaning Failures of ExtraCorporeal Life Support - ECLS</brief_title>
  <acronym>Weanilevo</acronym>
  <official_title>Interest of Levosimendan in Reducing Weaning Failures of ExtraCorporeal Life Support - ECLS. Randomized, Controlled, Multicenter, Double-blind, Multicenter Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extracorporeal life support (ECLS) is a circulatory cardio supplementation technique; it
      therefore makes it possible to compensate for a defective cardiac or cardio-respiratory
      function. ECLS nevertheless remains a temporary assistance technique pending a potential
      recovery of cardiac function, or it can be used to direct patients towards a heart transplant
      or long-term circulatory assistance (Left Ventricular Assist Device (LVAD) or Total Heart).
      In patients with complete or partial recovery of cardiac and circulatory function, ECLS
      withdrawal may be considered. Withdrawal from ECLS remains a delicate phase and the risk of
      failure is high. The mechanism of action of levosimendan, a drug that increases the
      contractility of the heart, suggests that it would improve the heart-vessel connection and
      reduce the rate of ECLS withdrawal failure. The effect of levosimendan is maximal 24 to 48
      hours after the end of the infusion and has a prolonged period of action.

      The objective is to evaluate the efficacy of levosimendan administration (0.2 µg/kg/min over
      24 hours) - versus placebo - prior to ECLS removal on the rate of withdrawal failure in
      patients under ECLS.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2019</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ECLS withdrawal failure</measure>
    <time_frame>7 days after ECLS removal</time_frame>
    <description>Withdrawal failure is defined as the absence of ECLS discontinuation or the use of temporary circulatory assistance such as ECLS, Impella® pump or intra-aortic balloon pump (IABP) or death</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">206</enrollment>
  <condition>Acute Decompensated Heart Failure</condition>
  <arm_group>
    <arm_group_label>Levosimendan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levosimendan</intervention_name>
    <description>Levosimendan 2.5mg/ml, solution to be diluted for infusion Dilution in a 500ml bag of 5% Glucose The product is administered as a continuous infusion for 24 hours at an initial rate of 0.2 µg/kg/min</description>
    <arm_group_label>Levosimendan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cernevit</intervention_name>
    <description>mixture of 12 vitamins The dilution of the treatment is done in a 500ml bag of 5% Glucose The product is administered as a continuous infusion for 24 hours at an initial rate of 0.2 µg/kg/min</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patient

          -  patient or person responsible for the patient has given written consent

          -  patient with severe chronic heart failure in acute decompensation under ECLS

          -  patient meeting criteria for ECLS withdrawal

               -  ECLS flow rate at 1.0-1.5l/min and/or ECLS pump rpm ≤ 1500 rpm

               -  LVEF &gt; 20% in cardiac ultrasound and aortic ITV &gt; 10 cm

               -  VIS score ≤ 10

               -  Arterial lactates ≤ 2 mmol/l

               -  Right ventricular outflow tract shortening fraction &gt; 30%

               -  Basal diameter at the tricuspid telediastolic ring of the right ventricle &lt; 35 mm

               -  Fraction of inspired oxygen combined between ventilator and ECLS &lt; 80%

          -  ECLS withdrawl scheduled within 48 hours

          -  Absence of an initial or progressive infectious episode (no planned introduction of
             antibiotic therapy within 48 hours)

        Exclusion Criteria:

          -  Patient with hepatic insufficiency: cytolysis at least 20 times normal

          -  Patient with a contraindication to the use of levosimendan:

               -  hypersensitivity to the active substance or any of the excipients

               -  severe hypotension and ventricular tachycardia

               -  significant mechanical obstructions affecting ventricular filling and/or ejection

               -  severe renal failure (creatinine clearance &lt; 30 ml/min)

               -  severe liver failure (TP&lt;50%)

               -  history of torsades de pointes

          -  Patient with a contraindication to the use of CERNEVIT®:

               -  hypersensitivity to active substances, in particular to vitamin B1 or to one of
                  the excipients or to soy protein products or to peanut protein products

               -  hypervitaminosis to any vitamin contained in this formulation

               -  severe hypercalcemia, hyper calciuria, tumour, bone metastasis, primary
                  hyperparathyroidism, granulomatosis

          -  patient not affiliated to or not benefiting from national health insurance

          -  patient subject to legal protection (curatorship, guardianship)

          -  patient subject to limited judicial protection

          -  pregnant, parturient or breastfeeding woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mohamed Omar ELLOUZE</last_name>
    <phone>03.80.29.32.62</phone>
    <phone_ext>+33</phone_ext>
    <email>mohamedomar.ellouze@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mohamed Omar ELLOUZE</last_name>
      <phone>03 80 29 32 62</phone>
      <phone_ext>+33</phone_ext>
      <email>mohamedomar.ellouze@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 7, 2019</study_first_submitted>
  <study_first_submitted_qc>November 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2019</study_first_posted>
  <last_update_submitted>November 7, 2019</last_update_submitted>
  <last_update_submitted_qc>November 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simendan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

